Even though older adults were prescribed second-line therapies less frequently than younger adults, patients had similar overall survival outcomes across age subgroups.
In this study, a young adult was defined as an individual who was 40 years or younger.
Even after adjustment for tumor stage, patients with ulcerative colitis have higher risk for CRC mortality.
The decision to adopt bevacizumab could be appraised by the prior level of uptake among their peers in their medical community.
After colorectal cancer screening guidelines lowered the age at which to start screening to age 45 years, increased screening rates followed among younger individuals.
Without a “clear” overall survival benefit from maintenance therapy, observation remains an option for patients with metastatic colorectal cancer.
NCI-MATCH trial identified additional patients who may benefit from nivolumab.
Increase in screening rates in quarters 3, 4 of 2018 versus quarter 1; no change for people in their 50s
Researchers assessed the relationship between gout and colorectal cancer in a cohort of veterans.
The one criticism that has persisted is the concern that a portion of patients on the control arm of the BEACON trial did not previously receive oxaliplatin.
